Piramel Alzheimer's imaging agent gets EU thumbs up
This article was originally published in Clinica
The EU's CHMP last week granted a positive opinion to marketing for another imaging agent for use in Alzheimer's disease, Piramal Imaging's NeuraCeq (florbetaben). It gave the go-ahead for Lilly and Avid Radiopharmaceuticals' Amyvid (florbetapir F 18 injection in October 2012, which was then the first imaging agent of its kind to be approved in the EU in January this year; Amyvid was approved in the US earlier in April that year. GE Healthcare's similar product Vizamyl (18F flutemetamol) recently received US approval.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.